Scientists focussing on cardiometabolic diseases are strongly interested in the extensive interactions between pathologically altered metabolism and cardiovascular diseases.

The multidisciplinary research of the scientists at the Medical Faculty deals with neuropsychiatric diseases focusing on misdirected neuronal networks (circuits) as biological causes for neuropsychiatric symptom domains, e. g. cognition, impulsiveness, anhedonia or fear. That research includes topics such as epigenetic embossing of traumatic stressors, mechanisms of synaptic plasticity and cortical disinhibition.

RBB acts as a "radar" for the next big wave of innovation by fostering emerging therapeutic concepts and technologies to advance drug discovery for diseases with high unmet medical need. 
We are open to new and disruptive ideas capturing emerging science in uncharted spaces targeting diseases currently devoid of effective therapies, including rare and genetic diseases. RBB advances projects through external collaborations with academic or biotech partners. Specific interests include but are not limited to potential therapeutic concepts in neuroprotection and endometriosis. Curative solutions based on tissue-selective adeno-associated virus (AAV) gene therapy or technological advances addressing, e.g., the spatio-temporal control of cargo expression or the modulation of immune responses, are of high interest as well.